Responses
Regular and young investigator award abstracts
Clinical trials in progress
417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.